Complement biomarkers during iptacopan treatment – Authors' reply

DK is scientific founder of and holds stock in Gyroscope Therapeutics; received consultancy fees from Achillion, Alexion, AstraZeneca, Catalyst, Chemocentryx, Novartis, Roche, and Silence Therapeutics; received grants or contracts from Gyroscope Therapeutics, Kidney Research UK, Macular Society, Medical Research Council, and the Wellcome Trust; and his spouse works for GSK. ASB received consulting fees from Achillion, Alexion, Amgen, Apellis, Catalyst, GSK, Novartis, Otsuka, and Silence Therapeutics. MV received honoraria for advisory boards and consulting fees from Alexion, Apellis, Bayer, Chinook Therapeutics, Novartis, PureSpring, Roche, Retrophin/Travere, Santhera, and SOBI; received honoraria for lectures, speaker bureaus, or educational events from Alexion, Cambridge Medical, Novartis, Roche, SOBI, and WebMD; participated in the European Union C4C (conect4children); participated in managed access programmes for Alexion, Novartis, and SOBI; and participated as Principal Investigator in clinical studies sponsored by Alexion, Apellis, Bayer, Boehringer Ingelheim, Chemocentryx, Chinook Therapeutics, Novartis, Roche, and Retrophin/Travere. CMN reports clinical trial research support from Achillion, Apellis, Biocryst Pharmaceuticals, Novartis, and Travere; consulting fees from Alexion, Apellis, Novartis, SilenceTherapeutics, and Vertex; royalties from UpToDate; and participation on a data safety monitoring board for Kira. RJHS reports research funding from the National Institute for Health and Care Research; is on an advisory board for Novartis; and is the Director of Molecular Otolaryngology and Renal Research Laboratories. The APPEAR-C3G trial (NCT04817618) was funded by Novartis. Medical writing support was provided by Carol Crawford at Novartis (funded by Novartis) , underthe direction of the authors and in accordance with good publication practice guidelines.